Developmental and Epileptic Encephalopathy clinical trials at UCSF

2 in progress, 1 open to eligible people

Developmental and epileptic encephalopathy is characterized by severe seizures impacting brain development. UCSF is running trials on LP352 to study its effects on individuals with this disorder. The trial involves a comparison of responses between those receiving the actual drug and those getting a placebo.

Showing trials for

  • LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

    open to eligible people ages 2-65

    This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.

    San Francisco, California and other locations

  • Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

    Sorry, in progress, not accepting new patients

    Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).

    San Francisco, California and other locations

Last updated: